Benchmark Holdings (BMK) has reported an overall positive H1’17 trading statement, demonstrating that it is leveraging its expertise across its Breeding and Genetics, Animal Health and Animal Nutrition platforms. Highlights of the H1’17 include formation of a new JV with SalMar ASA, the third largest salmon producer in the world. Meanwhile, softness in the shrimp markets continued, as flagged at the FY’16 results. Looking forward to H2’17, launch of a novel sea lice treatment is anticipated leading to significant revenues. The treatment, a follow up to Salmosan, will be an important addition to the company’s suite of sea lice control products to address this ongoing marine disease challenge.
26 May 2017
A leading edge in aquaculture
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
A leading edge in aquaculture
Benchmark Holdings Plc (BMK:LON) | 43.2 0 0.0% | Mkt Cap: 319.1m
- Published:
26 May 2017 -
Author:
Emma Ulker -
Pages:
2
Benchmark Holdings (BMK) has reported an overall positive H1’17 trading statement, demonstrating that it is leveraging its expertise across its Breeding and Genetics, Animal Health and Animal Nutrition platforms. Highlights of the H1’17 include formation of a new JV with SalMar ASA, the third largest salmon producer in the world. Meanwhile, softness in the shrimp markets continued, as flagged at the FY’16 results. Looking forward to H2’17, launch of a novel sea lice treatment is anticipated leading to significant revenues. The treatment, a follow up to Salmosan, will be an important addition to the company’s suite of sea lice control products to address this ongoing marine disease challenge.